Uniquity Bio is emerging from stealth with an FDA acceptance of its Phase 2 investigational new drug (IND) application for solrikitug, a monoclonal antibody targeting TSLP, and up to
The company aims to deliver best-in-class efficacy with solrikitug across several critical respiratory and GI indications with significant unmet needs. In the next month, Uniquity Bio will launch Phase 2 clinical trials in chronic obstructive pulmonary disease (COPD) - the third leading cause of death worldwide, according to the
'Our investment in Uniquity Bio illustrates Blackstone Life Sciences' commitment to finding, developing and delivering potentially transformative medicines to patients around the world,' said
Solrikitug is a highly potent anti-TSLP monoclonal antibody, which prevents the binding of TSLP to its receptors. Given TSLP's position as the 'master switch' cytokine sitting at the top of the inflammatory cascade, solrikitug could have potential utility in a wide array of immunology and inflammation programs. Solrikitug was in-licensed from
'We believe solrikitug has the potential to be a life-changing medication for a significant number of patients
Uniquity Bio was founded by industry executives with an extensive track record of developing new therapeutics in immunology and inflammation, and successfully advancing many clinical programs from development through commercialization. With Blackstone Life Sciences supporting the company's capital requirements, Uniquity Bio has a unique and sustainable business model that supports the parallel development of high-potential medicines along with a range of collaboration structures for maximum value.
The need - and market interest in the field of immunology and inflammation are extensive and growing, as the global immunology market is projected to skyrocket from
'As a nimble startup with a proven leadership team, we believe Uniquity Bio is well-positioned to develop promising therapeutics in this field and partner with leading global pharmaceutical companies,' said
ABOUT BLACKSTONE LIFE SCIENCES
Blackstone Life Sciences is an industry-leading private investment platform with capabilities to invest across the life cycle of companies and products within key life science sectors. By combining scale investments and hands-on operational leadership, Blackstone Life Sciences helps bring to market promising new medicines and medical technologies that improve patients' lives and currently has more than
ABOUT UNIQUITY BIO
Uniquity Bio is a clinical-stage drug development company built by biopharmaceutical executives with a proven track record and backed by Blackstone Life Sciences. The company is specifically structured to identify and advance therapeutic programs in immunology and inflammation with the scientific rigor and quality standards of a global pharma company, the operational agility of a biotech startup and a laser focus on improving patients' lives. With a unique and sustainable business model, Uniquity Bio is actively building an immunology and inflammation pipeline. Its first lead asset is solrikitug, a monoclonal antibody targeting TSLP. The company anticipates delivering best-in-class efficacy in multiple respiratory and gastrointestinal indications with significant unmet needs.
Contact:
Email: Paula.chirhart@blackstone.com
Tel: (347) 463-5453
Email: audrafriis@sambrown.com
Tel: (917) 519-9577
(C) 2024 Electronic News Publishing, source